CytomX Therapeutics, Inc.
CTMXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How CytomX Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 11 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 22, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Forefront Analytics, LLC | 2026-03-31 | 12,476 | $58.6K | SEC filing |
| BANK OF AMERICA CORP /DE/ | 2026-03-31 | 10,202,785 | $48M | SEC filing |
| HB Wealth Management, LLC | 2026-03-31 | 50,000 | $235K | SEC filing |
| DEUTSCHE BANK AG\ | 2026-03-31 | 463,421 | $2.18M | SEC filing |
| SCHULHOFF & CO INC | 2026-03-31 | 477,550 | $2.24M | SEC filing |
| WELLS FARGO & COMPANY/MN | 2026-03-31 | 6,595 | $31K | SEC filing |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2026-03-31 | 128,796 | $605K | SEC filing |
| DIMENSIONAL FUND ADVISORS LP | 2026-03-31 | 1,930,920 | $9.07M | SEC filing |
| Burkehill Global Management, LP | 2026-03-31 | 225,000 | $1.06M | SEC filing |
| BlackRock, Inc. | 2026-03-31 | 5,228,280 | $24.6M | SEC filing |
| TWO SIGMA INVESTMENTS, LP | 2026-03-31 | 2,710,156 | $12.7M | SEC filing |
| BAKER BROS. ADVISORS LP | 2026-03-31 | 4,975,826 | $23.4M | SEC filing |
| MILLENNIUM MANAGEMENT LLC | 2026-03-31 | 3,660,190 | $17.2M | SEC filing |
| ROYAL BANK OF CANADA | 2026-03-31 | 742 | $3K | SEC filing |
| Pictet Asset Management Holding SA | 2026-03-31 | 16,606 | $78K | SEC filing |
| Soleus Capital Management, L.P. | 2026-03-31 | 300,000 | $1.41M | SEC filing |
| Scientech Research LLC | 2026-03-31 | 230,598 | $1.08M | SEC filing |
| SPHERA FUNDS MANAGEMENT LTD. | 2026-03-31 | 220,000 | $1.03M | SEC filing |
| OSAIC HOLDINGS, INC. | 2026-03-31 | 16,471 | $77.4K | SEC filing |
| Engineers Gate Manager LP | 2026-03-31 | 29,477 | $139K | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among CytomX Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-03-17 · McCarthy Sean A.: Larger than all 46 other insider sales of Common Stock on file. SEC filing
- 2025-06-16 · McCarthy Sean A.: Larger than 43 of the 46 other insider sales of Common Stock on file. SEC filing
- 2025-03-18 · McCarthy Sean A.: Larger than 42 of the 46 other insider sales of Common Stock on file. SEC filing
- 2021-06-16 · McCarthy Sean A.: Larger than 44 of the 46 other insider sales of Common Stock on file. SEC filing
- 2021-03-31 · McCarthy Sean A.: Larger than 44 of the 46 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-15 | Ogden Christopher · Chief Financial Officer | Common Stock | S — Open market or private sale | −1,624 | 3.05 | SEC filing |
| 2026-03-17 | McCarthy Sean A. · CEO | Common Stock | S — Open market or private sale | −118,969 | 6.42 | SEC filing |
| 2026-03-17 | Ogden Christopher · Chief Financial Officer | Common Stock | S — Open market or private sale | −19,323 | 6.42 | SEC filing |
| 2026-03-17 | BELVIN MARCIA · SVP, Chief Scientific Officer | Common Stock | S — Open market or private sale | −31,492 | 6.42 | SEC filing |
| 2026-03-17 | Chu Yu-Waye · Chief Medical Officer | Common Stock | S — Open market or private sale | −21,279 | 6.42 | SEC filing |
| 2025-11-06 | McCarthy Sean A. · CEO | Class A Common Stock | S — Open market or private sale | −101,793 | 4.54 | SEC filing |
| 2025-06-16 | Ogden Christopher · Chief Financial Officer | Common Stock | S — Open market or private sale | −10,614 | 2.69 | SEC filing |
| 2025-06-16 | BELVIN MARCIA · SVP, Chief Scientific Officer | Common Stock | S — Open market or private sale | −13,884 | 2.69 | SEC filing |
Showing 8 of 11 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-17 | Ashworth Alan · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +59,000 | SEC filing |
| 2026-06-17 | Jones Elaine V · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +59,000 | SEC filing |
| 2026-06-17 | Su Zhen · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +59,000 | SEC filing |
| 2026-06-17 | Meyers James R · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +59,000 | SEC filing |
| 2026-06-17 | Young Matthew P. · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +59,000 | SEC filing |
| 2026-06-17 | Mohindru Mani · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +59,000 | SEC filing |
| 2026-06-17 | Gilbert Halley E · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +59,000 | SEC filing |
| 2026-02-02 | Lester Rachael · Chief Business Officer | Common Stock | A — Grant, award, or other acquisition | +20,000 | SEC filing |
Showing 8 of 21 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.